Lot-document scope confirmed before quotation · Research use only
  • Specification Review
  • Lot Documents on Request
  • Business Support · Xi’an
  • Destination Eligibility Confirmed
西安诺和达生物科技有限公司
For research, development and manufacturing use only. Not for human or veterinary use.

Growth Hormone & IGF · Source-reviewed dossier

Hexarelin Acetate

Source-Reviewed Research Dossier

Hexarelin acetate is a synthetic peptide studied for its effects on growth-hormone release and, separately, on the heart and blood vessels. It acts like ghrelin, the body's natural signal, by switching on the same receptor. There is also a hypothesis that it interacts with CD36, a protein on heart cells, without involving growth hormone. However, most heart-related evidence comes from mechanistic or animal experiments, not controlled human outcome studies. A review describes hypotheses rather than confirmed clinical benefit. This catalog material is intended for laboratory research only, not for human use.

Research use only Lot documents on request
Hexarelin Acetate research product family with 2 catalog variants
AI-generated packaging mockup for catalog navigation. It is not a photograph of an actual supplied lot; container, label and presentation may vary.

Product family

Compound overview

Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; request the applicable product specification and ask which lot records are available before ordering.

Product identity

Product type
Peptide research compound
Catalog family
Hexarelin Acetate
Research category
Growth Hormone & IGF
Catalog CAS RN
140703-51-1
Catalog molecular formula
C47H58N12O6
Catalog molecular weight
887.04 g/mol
Catalog sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
Evidence status
Mechanistic and preclinical cardiovascular literature; limited clinical-outcome evidence
Intended use
Research, development and manufacturing use only

Literature reference parameters

Compound or material class
Synthetic hexapeptide GH secretagogueCatalog-family identity
Evidence scope
Mechanistic and preclinical cardiovascular literature; limited clinical-outcome evidenceDo not generalize beyond the cited model
Source review
Primary or authoritative records linked belowChecked 2026-09-01

Identity safeguard Reference identifiers above describe the literature compound record. Confirm the supplied form, formula, molecular weight, purity and storage conditions against the applicable product specification and any available lot records.

Mechanism of action

How Hexarelin Acetate is studied

A target-to-pathway view grounded in the linked research records.

Ghrelin receptor triggers growth hormone

Hexarelin activates the ghrelin receptor, the same switch the body uses to release growth hormone. This receptor is found in the brain and also in blood vessels and heart tissue. Activating it in the brain prompts the pituitary, a small gland near the brain, to release growth hormone. This receptor action is the best-established part of hexarelin's biology.

Heart effects without growth hormone

Some research suggests hexarelin may bind to CD36, a protein on the surface of heart cells, and that this could explain protective effects seen in heart models. If true, these effects would not require growth-hormone release. However, this idea comes mainly from mechanistic and animal experiments, so it remains a hypothesis about how the peptide might work, not a proven clinical effect. It is a major reason hexarelin is studied beyond growth-hormone research.

Kidney injury study in rats

A 2023 animal study tested hexarelin before a kidney injury caused by restricted blood flow and reflow in rats. It reported less tissue damage and reduced cell death, with changes in proteins related to apoptosis, a type of programmed cell death. This was a pretreatment study in a preclinical model, not a treatment study, and it concerned kidneys, not the heart. It suggests hexarelin might influence cell-survival pathways, but cannot be translated into human dosing, safety, or benefit.

Evidence level and limitations

The strongest supported statements are receptor activity and preclinical observations. A focused review summarizes cardiovascular hypotheses from mixed evidence, and the kidney work is animal and cell based. No controlled human outcome trial is cited here. So claims about cardiac protection in people, or about any research material producing a particular biological result, go beyond what the supplied records show. Identity and lot quality are separate analytical matters, not evidence of effect.

Reported research findings

What published studies report about Hexarelin Acetate

Reported outcomes are paired with their experimental model and evidence boundary.

Mechanism review

Cardiovascular actions were summarized from mixed evidence

A focused review describes GH-dependent and GH-independent cardiovascular hypotheses for hexarelin.

Review-level mechanisms do not establish clinical efficacy.

Read the primary study
Animal study

Renal ischemia-reperfusion outcomes were preclinical

A 2023 study reported apoptosis-related outcomes in an ischemic acute-kidney-injury model.

The experiment does not support human treatment or catalog-lot claims.

Read the primary study
Translation boundary: findings are limited to the evidence level stated on each card. Experimental protocol quantities are research details, not usage instructions.

Catalog options

Variant specifications

Pack-level catalog data; lot-level controls remain document-specific.

Catalog no.HX2
Pack size2 mg × 10 vials
Specification & documents for HX2

Product specification

Single-component peptide · 2 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Catalog no.HX5
Pack size5 mg × 10 vials
Specification & documents for HX5

Product specification

Single-component peptide · 5 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.

Lot documentation

Document availability and scope must be confirmed for this variant and lot in the written quotation. A catalog description is not a lot-specific test result.

Quality system

Quality documentation

A listed document is not proof of availability for this lot. Ask the team to confirm the current COA status and the scope of any other records before ordering.

Lot-specific Certificate of AnalysisAvailability and scope must be confirmed for the selected catalog variant and lot
COA availability unconfirmed Ask about availability
Product Specification SheetAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request
Analytical Method SummaryAvailability and scope must be confirmed for the selected catalog variant and lot
Confirm before ordering Request

Analytical interpretation

Interpret the documents, not just the headline number.

Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.

Open the Quality & Documentation Hub

HPLC area ≠ assayA dominant peak does not establish target mass fraction.

Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.

Counterions affect contentWater, salt form and solvents change the as-is composition.

Storage needs a data basisShipping practice is not the same as stability evidence.

Evidence map

Research context

Published studies and regulatory records, not customer testimonials or usage guidance.

Mechanism review

Cardiovascular actions were summarized from mixed evidence

Review-level mechanisms do not establish clinical efficacy.

View primary record
Animal study

Renal ischemia-reperfusion outcomes were preclinical

The experiment does not support human treatment or catalog-lot claims.

View primary record
Evidence boundary: each card states its evidence type. Human trials and regulatory records describe the studied or regulated intervention; preclinical records remain model-specific. None verifies the identity, quality, safety or efficacy of this catalog lot or provides usage instructions.

Literature basis

Curated references

Third-party publications selected for direct relevance.

  1. 01

    The cardiovascular action of hexarelin

    Mao Y, et al. Journal of Geriatric Cardiology. 2014. PMID 25278975.

    Mechanism review
  2. 02 Animal study

Research FAQ

Hexarelin Acetate questions

Concise answers for researchers comparing identity, evidence and catalog variants.

What effects are studied for Hexarelin Acetate?

The clearest action is activation of the ghrelin receptor, which leads to growth-hormone release. Researchers have also proposed a second route involving CD36 on heart cells that could act without growth hormone. That cardiac idea comes mainly from mechanistic and animal experiments, not controlled human outcome studies, so it should be read as a research hypothesis rather than a demonstrated effect in people.

How should the Hexarelin Acetate research findings be understood?

The strongest supported statements are receptor activity and preclinical observations. A focused review summarizes cardiovascular hypotheses from mixed evidence, and the kidney work is animal and cell based. No controlled human outcome trial is cited here. So claims about cardiac protection in people, or about any research material producing a particular biological result, go beyond what the supplied records show. Identity and lot quality are separate analytical matters, not evidence of effect.

What evidence is available for Hexarelin Acetate?

The public evidence is dominated by reviews and preclinical cardiovascular or renal models.

Does the cited research validate this catalog material?

No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.

Which quality documents can be requested?

A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.

How should Hexarelin Acetate be stored?

Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.

Knowledge center

Related insights

Owned educational content connected to this family.

Hexarelin editorial illustration

Hexarelin Human Evidence: Dose Response, GH Peak and Limits

Hexarelin has controlled human pharmacology data, but the central evidence is an acute 12-person GH dose-response experiment rather than a clinical-outcome trial.

Updated October 1, 2026

Knowledge tools

Continue with structured evidence

Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.

Internal technical source review

Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.

Editorial status: NHD evidence editorial workflow · 2026-09-01 · Not independent medical review · Review policy

Technical procurement

Ready to request a quote?

Selected: HX2 · 2 mg × 10 vials